#Germany #Milan #Kexing Biopharm #Innovative Drugs #CPHI Milan

Kexing Biopharm Highlighted at CPHI Milan 2026

Introduction
From October 6 to 8, 2026, Kexing Biopharm (688136.SH) participated in the prestigious CPHI Milan event, showcasing its impressive global portfolio of innovative pharmaceutical products. This year's exhibition served as a platform for the company to establish connections with pharmaceutical buyers, biotech firms, and industry partners from across the globe.

Expanding Global Reach
In recent years, Kexing has developed a robust framework for international marketing and has entered into cooperation agreements with several domestic pharmaceutical companies for more than 30 products targeting foreign markets. The company's distribution network spans approximately 70 countries and regions, with nearly 200 registration applications submitted overseas. Europe stands out as a pivotal market for Kexing, particularly its flagship product, Albumin-bound Paclitaxel, which is already marketed within the EU, UK, and other territories.

To tap into unmet clinical needs and market potential, Kexing is also working on over 10 high-quality biosimilars tailored for global markets. To consolidate its presence in Europe, the company has established a subsidiary in Germany and is advancing plans to launch branches in France, Spain, Italy, the UK, the Netherlands, and beyond. These local offices will enhance Kexing's ability to respond effectively to regional customer demands and foster long-term partnerships. The company's participation in CPHI events over the years has created vital networking opportunities to deepen its foothold in the region and engage directly with local industry partners.

Commitment to Innovation
Kexing Biopharm’s strategic focus centers on “Innovation + Internationalization.” During CPHI Milan 2026, the firm drew attention with its innovative drug candidates in various therapeutic areas, including cancer cachexia, ophthalmological treatments, systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD). Several development programs target markets with long-term chronic conditions and unmet clinical needs, showcasing Kexing’s commitment to addressing critical healthcare challenges.

Quality Assurance
The cornerstone of Kexing's global expansion is product quality. With three decades of experience in industrial-scale biopharmaceuticals, the company has established advanced manufacturing and quality management systems. The production line for Albumin-bound Paclitaxel has attained EU-GMP certification, ensuring that the product is approved in over 40 countries and regions.

Future Prospects
Looking ahead, Kexing Biopharm continues to advance its innovation and marketing strategies aimed at high-quality medication. The company remains dedicated to partnering with global stakeholders to promote improved health outcomes worldwide. Through these efforts, Kexing is poised to play a significant role in the future of pharmaceuticals, shaping the industry through its commitment to excellence, innovation, and international cooperation.